Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 826

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 826
---
      |   |     |      |   |

E. Income taxes included under profit or loss

|                                          |     | Year that ended on December 31 |     |      |     |      |
|                                          |     |                           2024 |     | 2023 |     | 2022 |
|                                          |     |               USD in thousands |     |      |     |      |
| Deferred taxes, see also Section D above |     |                              7 |     |   54 |     |   50 |

Note 17: — Contingent liabilities and COMMITMENTS A.For information regarding the contingent liability to the IIA (see Note 12). B.On May 31, 2009, the Company signed a research agreement and a license agreement with a third party, according to which the third party would perform research for the Company for three years in accordance with a predetermined research plan in exchange for a payment of USD $480 thousand. In addition, a third party granted the Company a license to use the technology it had developed in exchange for royalties equal to 5% of product sales and the provision of drug scanning services for a period of 15 years from the date the Company’s sales commence, as well as 20% of the proceeds from the sale of sub -licensesby the Company. In case the Company is obligated to pay royalties to another party in connection with the same product, the aforementioned royalty rate shall be reduced to 3.5% and 15%, respectively. In May 2013, the Company signed an amendment to the agreement. According to the amendment, the third party would perform research for the Company for another four years in accordance with a predetermined research plan in exchange for a payment of USD $480 thousand. In addition, the Company would pay royalties equal to 5% of the Company’s revenues from product sales and the provision of drug scanning services, and 20% of the proceeds from the sale of sublicenses by the Company, as well as royalties at rates ranging from 2% to 7.5% for the sale of drug scanning products and additional receipts that the Company would receive from these products. In case the Company is obligated to pay royalties to another party in connection with the same product, the aforementioned royalty rate shall be reduced to 3.5%, 15%, and a rate ranging from 1.4% to 5.25%, respectively. On January 19, 2016, the Company entered into an addendum to the agreement